FDA approves neoadjuvant/ adjuvant pembrolizumab for …
WEBOn October 16, 2023, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of...
Adjuvant Keytruda Improves Kidney Cancer Survival - NCI
WEBMay 21, 2024 · Pembrolizumab (Keytruda) treatment after surgery helped people with clear-cell renal cell carcinoma live longer in a large trial—a first for this cancer.
FDA approves pembrolizumab as adjuvant treatment for non …
WEBOn January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB...
Pembrolizumab improves outcomes in high-risk bladder cancer
WEBSep 16, 2024 · NCI Press Office. 240-760-6600. Adjuvant pembrolizumab helps people with muscle-invasive bladder cancer remain cancer-free longer than observation alone. Credit: Terese Winslow/National Cancer Institute. Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk ...
FDA approves pembrolizumab with chemotherapy for …
WEBOn June 17, 2024, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) with carboplatin and paclitaxel, followed by single-agent pembrolizumab, for adult patients with...
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative …
WEBJul 20, 2022 · Pembrolizumab monotherapy has shown durable antitumor activity in advanced triple-negative breast cancer, 6-9 particularly as first-line therapy, with improved clinical responses observed among...
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of ... - Merck
WEBJul 27, 2021 · FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With High-Risk Early-Stage Triple-Negative Breast Cancer in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Single Agent as Adjuvant Treatment After Surgery. Save. July 27, 2021 6:30 am ET.
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined …
WEBMay 5, 2021 · KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥10) as determined by an FDA-approved test.
Pembrolizumab to Prevent Early-Stage Melanoma Recurrence
WEBOct 13, 2021 · Patients who received the immunotherapy pembrolizumab (Keytruda) after surgery to remove high-risk stage II melanomas were less likely to have the cancer come back than those who received no post-surgical treatment, new study results show.
FDA Approves Neoadjuvant/Adjuvant Pembrolizumab for …
WEBOn 16 October 2023, the US Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of single-agent pembrolizumab as post-surgical adjuvant treatment for resectable (tumours ≥4 cm or node positive) non-small cell lung cancer (NSCLC).
Skip to content